FORTREA DEVELOPMENT LIMITED

1. FORTREA DEVELOPMENT LIMITED 2023-04-28 → present
2. LABCORP CLINICAL DEVELOPMENT LIMITED 2021-06-25 → 2023-04-28
3. COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED 1996-11-04 → 2021-06-25
4. CORNING BESSELAAR LIMITED 1995-04-10 → 1996-11-04
5. G. H. BESSELAAR ASSOCIATES LIMITED 1986-12-16 → 1995-04-10
6. HACKREMCO (NO.280) LIMITED 1986-05-23 → 1986-12-16

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

AAB Audit & Accountancy Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At the time of approving the financial statements, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

1. FORTREA DEVELOPMENT LIMITED · parent
   1. Fortrea Austria GmbH 100% · Austria · Clinical research into pharmaceutical drug development
   2. Fortrea Turkey Klinik Arastirma Limited Sirketi 99% · Clinical research into pharmaceutical drug development
   3. Fortrea Clinical Research Unit Limited 100% · Contract biological and chemical research
   4. Fortrea Denmark ApS 100% · Denmark · Clinical research into pharmaceutical drug development
   5. Fortrea South Africa (Pty) Ltd 100% · South Africa · Clinical research into pharmaceutical drug development
   6. Fortrea Development Ukraine LLC 100% · Ukraine · Clinical research into pharmaceutical drug development
   7. Fortrea Costa Rica SRL 95% · Costa Rica · Clinical research into pharmaceutical drug development

Significant events

• “On June 2, 2025, a purported shareholder class action complaint captioned Lucas Deslande v. Fortrea Holdings Inc., et al., No 1:25-sv-04630 was filed in the U.S. District Court for the Southern District of New York, naming Fortrea Holdings Inc., which is the ultimate parent company of the Fortrea Development Limited and certain of its current and former officers as defendants.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -0.9%

  £191,341,000 → £189,585,000

• Cash

  -30.5%

  £12,981,000 → £9,028,000

• Net assets

  -1.5%

  £105,448,000 → £103,821,000

• Employees

  -7.9%

  2,105 → 1,938

• Operating profit

  +61%

  £13,441,000 → £21,637,000

• Profit before tax

  +571.7%

  £9,891,000 → £66,437,000

• Wages

  -2.6%

  £116,818,000 → £113,816,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers